About 9 of 10 novel APIs are chiral. Enzymes are stereoselective and therefore are well suited for the synthesis of APIs or new chemical entities. Beside product innovations, the generic industry needs to bear a cost pressure by reducing manufacturing costs. Both challenges can be faced by the application of customised, highly efficient enzymatic solutions. Karyotica has certain important enzymes required for enzymatic synthesis in the pharmaceutical industry.